Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nisevokitug - Novartis

Next Previous
Drug Profile

Nisevokitug - Novartis

Alternative Names: Anti-TGF beta antibody - Novartis; NIS-793

Latest Information Update: 29 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator XOMA
  • Developer Novartis
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer
  • Phase I/II Myelofibrosis
  • No development reported Myelodysplastic syndromes; Solid tumours
  • Discontinued Pancreatic cancer

Most Recent Events

  • 07 Aug 2025 Novartis terminates the phase I/II ADORE trial in Myelofibrosis (Combination therapy) in Australia, Spain, Belgium, Canada, Denmark, Hungary, Israel, Italy, Japan, South Korea, Netherlands, Romania, Russia, Sweden, Switzerland, Turkey, United Kingdom and Germany (PO), due to sponsor decision (NCT04097821)
  • 26 Mar 2025 Novartis Pharmaceuticals terminates the phase II daNIS-3 trial in Colorectal cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA, Australia, Belgium, Canada, Czech Republic, France, Germany, Hong Kong, Hungary, Israel, Italy, Japan, South Korea, Singapore, Spain, Switzerland, Taiwan and the UK (IV) due to the halt of NIS793 treatment and urgent safety measures (NCT04952753) (EudraCT2021-000553-40)
  • 28 Aug 2024 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes(Combination therapy, Second-line therapy or greater) in Australia (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top